Presence of anti-transcriptional intermediary factor-1 gamma antibodies in a dermatomyositis patient with retroperitoneal cancer of unknown primary site.


Journal

Modern rheumatology case reports
ISSN: 2472-5625
Titre abrégé: Mod Rheumatol Case Rep
Pays: England
ID NLM: 101761026

Informations de publication

Date de publication:
01 2021
Historique:
entrez: 3 12 2020
pubmed: 4 12 2020
medline: 21 9 2021
Statut: ppublish

Résumé

A 71-year-old woman with dermatomyositis (DM) received glucocorticoid steroid (GCS) and tacrolimus treatment. Relapse of skin symptoms was observed after tapering the GCS dose, and the patient tested positive for anti-transcriptional intermediary factor-1 gamma (TIF1-γ) antibody. Examinations for malignancy were repeatedly performed. However, no obvious findings indicative of a tumour were observed. Two years after, a retroperitoneal tumour was detected and pathologically diagnosed as poorly differentiated adenocarcinoma. The patient developed intestinal and biliary obstruction and eventually died of sepsis. Herein, we report the presence of anti-TIF1-γ antibodies in a DM patient with cancer of unknown primary site.

Identifiants

pubmed: 33269651
doi: 10.1080/24725625.2020.1789302
doi:

Substances chimiques

Autoantibodies 0
Transcription Factors 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

62-68

Auteurs

Hiroshi Hori (H)

Division of General Medicine, Department of Comprehensive Medicine 1, Saitama Medical Center, Jichi Medical University, Saitama, Japan.

Yusuke Ozeki (Y)

Division of General Medicine, Department of Comprehensive Medicine 1, Saitama Medical Center, Jichi Medical University, Saitama, Japan.

Tsuyoshi Kobashigawa (T)

Division of Rheumatology, Department of Comprehensive Medicine 1, Saitama Medical Center, Jichi Medical University, Saitama, Japan.

Kazusige Futsuhara (K)

Divison of Surgery, Department of Comprehensive Medicine 2, Saitama Medical Center, Jichi Medical University, Saitama, Japan.

Akira Tanaka (A)

Division of Pathology, Department of Comprehensive Medicine 2, Saitama Medical Center, Jichi Medical University, Saitama, Japan.

Eri Watanabe (E)

Division of Rheumatology, Department of Comprehensive Medicine 1, Saitama Medical Center, Jichi Medical University, Saitama, Japan.

Hiroki Yabe (H)

Division of Rheumatology, Department of Comprehensive Medicine 1, Saitama Medical Center, Jichi Medical University, Saitama, Japan.

Toru Yago (T)

Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan.

Takahiko Fukuchi (T)

Division of General Medicine, Department of Comprehensive Medicine 1, Saitama Medical Center, Jichi Medical University, Saitama, Japan.

Hitoshi Sugawara (H)

Division of General Medicine, Department of Comprehensive Medicine 1, Saitama Medical Center, Jichi Medical University, Saitama, Japan.

Shigeru Kotake (S)

Division of Rheumatology, Department of Comprehensive Medicine 1, Saitama Medical Center, Jichi Medical University, Saitama, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH